Chemical Name: (3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid
Biological ActivityATP citrate lyase (ACLY) inhibitor. Prodrug of SB 201076. Inhibits cholesterol and fatty acid synthesis in a dose-dependent manner in HepG2 cells. Orally active in vivo.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R*,5S*)-ω-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzy
Gribble et al.
The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076.
Pearce et al.
Citations for SB 204990
The citations listed below are publications that use Tocris products. Selected citations for SB 204990 include:
3 Citations: Showing 1 - 3
Polarization of Human Macrophages by Interleukin-4 Does Not Require ATP-Citrate Lyase.
Authors: Namgaladze Et al.
Front Immunol 2018;9:2858
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.
Authors: Chen Et al.
Nat Genet 2018;50:219
Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism.
Authors: Shah Et al.
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
Reviews for SB 204990
Average Rating: 5 (Based on 1 Review)
Have you used SB 204990?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
SB-204990 were used as an ACLY inhibitor in subconfluent endothelial cells. The images are shown in the publication PubMed ID 29429925.